Sermorelin Dosage in the Research Literature, by Study and Population

The short version

Sermorelin dosage on this page means one thing only: the amounts researchers gave, in studies, to learn how the peptide behaves. It is not a how-to. Children in the growth trial received about 30 micrograms per kilogram per day under the skin at bedtime ^[1]. Older men in the aging study received 0.5 to 1 mg under the skin twice a day for two weeks ^[2]. Pharmacology studies used tiny microgram-per-kilogram doses into a vein to measure the response ^[3]. Read these as study designs — what was tested — not as a personal recommendation, because none is given here.

Doses used in the research literature

Sermorelin dosage in the published record clusters by the question each study asked.

• Pediatric GH-deficiency efficacy: 30 mcg/kg/day subcutaneously at bedtime, in the multicenter trial that raised first-year height velocity from ~4.1 to 7-8 cm/year ^[1].
• Aging research in older men: 0.5 mg and 1 mg subcutaneously twice daily for 14 days, the regimen that reversed age-related GH and IGF-1 decreases at the high dose ^[2].
• Diagnostic GHRH stimulation: a single intravenous bolus (historically around 1 mcg/kg) used to test pituitary GH reserve.
• Pharmacokinetic work: intravenous doses of 0.25-2 mcg/kg, which elicited dose-dependent GH release in healthy men ^[3].

These are the doses studies administered. The site reports them as data points on the doses used in research; it does not translate them into a human-use regimen.

Routes studied

Three routes appear in the literature, with markedly different behavior. Subcutaneous injection is the primary route across the efficacy studies ^[1][2]. Intravenous dosing was used for the diagnostic and pharmacokinetic work, where GHRH(1-29)NH2 elicited GH release from 0.25 mcg/kg ^[3]. Intranasal delivery was examined historically but showed bioavailability of only 3-5% ^[3] — and oral, sublingual, and troche formulations are widely criticized in research-user communities as ineffective, because peptides degrade in the gut and absorb poorly across mucosa.

The route matters because the molecule is fragile. That fragility is also why the peptide is supplied as a lyophilized powder rather than a ready solution.

Half-life and timing in the studies

The pharmacokinetics set the rhythm of how sermorelin was dosed. The native peptide has a short plasma half-life on the order of 10-12 minutes after intravenous administration and is rapidly eliminated, yet a single dose elevates serum GH for roughly 3 hours ^[3]. That brevity, the literature notes, motivated longer-acting analogs via D-Ala2 substitution and the DAC technology behind CJC-1295 ^[10].

Timing, where studied, was deliberate: doses were often given at bedtime to align with the body's largest natural nocturnal GH pulse during slow-wave sleep, and GHRH's sleep-endocrine effects are time-of-day dependent ^[11]. This describes the timing used in research, not a personal-use instruction.

Handling and stability, as studied

Lyophilized sermorelin acetate is reconstituted with sterile diluent before study use; once reconstituted it is typically refrigerated, because aqueous peptide solutions degrade ^[3]. In a compounding context, preparations are made under USP <797> sterile-compounding standards — relevant to sermorelin's status as a Category 1 bulk drug substance under FDA's interim Section 503A policy ^[15]. The material discussed here is research-grade GHRH(1-29) handled for laboratory work.